The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic and resultant coronavirus infectious disease-2019 (COVID-19) create challenges and opportunities for physicians specializing in cell therapy and haematopoietic cell transplants. Recipients of these therapies are at high infection-risk because immune suppression and bone marrow failure from these therapies and their consequences such as cytokine release syndrome (CRS) and chronic graft-versus-host disease (GvHD) and from their underlying disease.